Sebastien Noel from Veeva Systems considers the potential benefits and drawbacks of messaging services for HCPs as well as explaining Veeva’s own platform, which combats these issues
7 April 2024
Alex Devereson and Delphine Zurkiya from McKinsey consider the value of generative AI in the pharma industry
7 April 2024
Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap
7 April 2024
Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates
7 April 2024
Santosh Sahu at Charac considers the NHS’ Pharmacy First scheme, it benefits and the barriers to its implementation
4 March 2024
Emma Bishop at Cognitant Group explores the need for patient support programmes, and how these can be improved
4 March 2024Sebastien Noel from Veeva Systems considers the potential benefits and drawbacks of messaging services for HCPs as well as explaining Veeva’s own platform, which combats these issues
7 April 2024Alex Devereson and Delphine Zurkiya from McKinsey consider the value of generative AI in the pharma industry
7 April 2024Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap
7 April 2024
Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere
7 April 2024Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates
7 April 2024
Betsy Goodfellow from Pharmafocus considers the current rise of measles cases in the UK and the measures that should be taken to prevent further infections
4 March 2024
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a maintenance therapy for patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) following stabilisation with an intravenous immunoglobin therapy (IVIG).
AbbVie has announced that the NICE has recommended Tepkinly (epcoritamab) as a treatment option for adults with diffuse large b-cell lymphoma (DLBCL) whose cancer has returned or not responded to two previous treatments.
The UKHSA has warned that further outbreaks of measles could spread to other towns and cities unless uptake in the measles, mumps and rubella vaccination is increased in at-risk areas.
Virocell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials.
AbbVie has announced that the MHRA has granted a marketing authorisation for Aquipta (atogepant), for the prophylaxis of migraine in adult patients who have had at least four migraine days each month.
Amicus Therapeutics has announced that the MHRA in the UK has granted marketing authorisation to pombiliti (cipaglucosidase alfa) and opfolda (miglustat) for the treatment of adult patients with late-onset pompe disease.
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited launch. The drug is intended to provide new treatment options to patients living with obesity.
Ministers have opened a new vaccine research centre at the UKHSA Porton Down campus in Wiltshire, intended to prepare for 'disease x', the next possible pandemic pathogen.
Bristol Myers Squibb has announced that NICE has recommended Sotyktu (deucravacitinib) for use on the NHS in England as a new treatment option for adult patients with moderate-to-severe plaque psoriasis.
Figures from a team at the University of York, the London School of Economics and Political Science (LSE), and the London School of Hygiene and Tropical Medicine (LSHTM) have revealed that the total cost of prescription medicines to NHS England reached a new high of £17.2bn in 2021-22, and that since 2018, NHS spending on branded medicines have been increasing by over 5% annually.
UK-based trade union Unite were pushing for staff walkouts at several GSK manufacturing sites due to disputes regarding pay increases, however to date there have been no updates as to whether GSK have extended another offer.
NHS England has announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs.
Otsuka Pharmaceuticals has announced that the National Institute for Health and Care Excellence (NICE) has recommended Lupkynis (Voclosporin) in combination with Mycophenolate Mofetil (MMF) as a treatment option for adult patients with active lupus nephritis (LN).
The National Institute for Health and Care Excellence (NICE) has announced that it is recommending two personalised immunotherapy treatments to the Cancer Drugs Fund (CDF) for the treatment of aggressive forms of blood cancers.
NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate cancer. This approval means men with advanced prostate cancer and women with her2-negative early breast cancer who are at high risk of the disease returning will be offered olaparib through the NHS in england. The decision has already received praise from charities and clinicians.
A new clinical trial is set to begin shortly, which will be a collaboration between the universities of Edinburgh, Aberdeen and Birmingham. The study will assess the efficacy of the drug dichloroacetate in managing pain for patients with endometriosis.
The FDA has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult patients with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate-to-advanced liver scarring (fibrosis), for use alongside diet and exercise.
Spero Therapeutics has announced that it has gained FDA clearance for the investigational new drug (IND) application to assess SPR206 in a phase 2 clinical study.
Johnson & Johnson (J&J) has announced that the FDA has approved Opsynvi (macitentan and tadalafil) for the chronic treatment of adults with pulmonary arterial hypertension (PAH).
AstraZeneca has announced that the FDA has approved Ultomiris (ravulizumab-cwvs) as the first and only long-acting c5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (aqp4) antibody-positive (ab+) neuromyelitis optica spectrum disorder (nmosd).
AstraZeneca has announced that the FDA has approved Tagrisso for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
GSK has announced that the FDA has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis b.
Johnson & Johnson has announced that the FDA has granted breakthrough therapy designation for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn.
Argenx has announced that the FDA has accepted a supplemental biologics license application (sBLA) for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for priority review.
Ipsen has announced that the FDA has approved the supplemental new drug application for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and ;eucovorin (Nalirifox) as a first-line treatment for adult patients with metastatic pancreatic adenocarcinoma (mpdac).
Merck has announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemoradiotherapy for the treatment of figo (international federation of gynecology and obstetrics) 2014 stage iii-iva cervical cancer.
Johnson & Johnson (J&J) has announced that the FDA has approved a supplemental new drug application for Balversa (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 genetic alterations whose disease has progressed on or after one prior treatment.
AstraZeneca and Ionis have announced that the FDA has approved Wainua (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (haattr-pn or attrv-pn) in adult patients.
Calliditas Therapeutics has announced that the FDA has approved Tarpeyo (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobin a nephropathy at risk of disease progression.
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/ml injection for intravenous use at the 16th annual clinical trials on Alzheimer’s disease conference in Boston, US on 24-27 October 2023.
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its nivolumab injection (ba1104) in china.
Merck, known as MSD outside of the US, has announced that the FDA has approved Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy, for first-line treatment of adult patients with locally advanced unresectable or metastatic her2-negative gastric or gastroesophageal junction adenocarcinoma.
AstraZeneca has announced that the European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (dato-dxd) in the treatment of two cancers.
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Awiqli (once-daily basal insulin icodec) for the treatment of diabetes in adult patients.
Pfizer has announced that the EC has granted marketing authorisation for Velsipity (etrasimod) in the EU.
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a crispr/cas9 gene-edited therapy.
GSK has announced that the CHMP of the EMA has given a positive recommendation to the company’s momelotinib for patients with myelofibrosis.
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia that is flt3-itd positive.
Roche has announced that the EC has approved the extension of Evrysdi’s marketing authorisation in the EU to include infants under two months with a clinical diagnosis of spinal muscular atrophy (SMA).
GSK has announced that ViiV healthcare has received a positive opinion from the EMA's CHMP, recommending marketing authorisation for cabotegravir long-acting (LA) injectable and tablets for HIV prevention.
The European Parliament has shared its recommendations for a ‘coordinated EU response to health threats posed by antimicrobial resistance,’ according to its press release.
The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The decision was previously expected on 29 March 2023, but has been announced to be “slightly later”.
Pharma giant AstraZeneca has been given a recommendation by the EU's Committee for Medicinal Products (CHMP) for marketing authorisation for ultomiris (ravulizumab), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMSOD) who are anti-aquaporin-4 (AQP4) antibody positive (ab+).
AbbVie has announced that it has received positive feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) recommending the approval of upadacitinib (rinvoq) for the treatment of adult patients with moderate to severe crohn’s disease who have had an inadequate response, lost response or were intolerant to conventional therapies or biologic agents.
CSL, a biotech company, has announced that it has received conditional marketing authorisation (CMA) from the European Commission (EC) for its haemophilia b drug hemgenix.
Life sciences giant Merck & Co has announced that it will appeal the EU's committee for Medicinal Products for Human Use’s (CHMP) decision to not recommend approval for its COVID-19 drug lagevrio.
Following the increase in respiratory infections, the continuing cost of living crisis and the Russia-Ukraine conflict, Europe is planning countermeasures for further antibiotic shortages
AstraZeneca has announced plans to open a new facility in Ireland, previously planned for northwest England
Welcome to the April 2024 issue of Pharmafocus!
Welcome to the March 2024 issue of Pharmafocus!
Welcome to the first Pharmafocus of 2024!
Welcome to the December 2023 issue of Pharmafocus!
Welcome to the November 2023 issue of Pharmafocus! This issue includes the latest news as well as fascinating articles.
Welcome to the October 2023 issue of Pharmafocus!
Nuclera has announced that it has appointed Joseph Bertelsen as chief commercial officer (CCO).
BenevolentAI has announced that Dr Daniel Neil, current chief technology officer (CTO) is stepping down, to be succeeded by Dr James Malone, who joins the company in April.
Vynamic has announced the appointment of Gemma Pfister as head of life sciences Europe.
Parexel has announced that its CEO, Jamie MacDonald will retire, with the company’s current chief operating and growth officer Peyton Howell taking over as CEO, effective 15 May 2024.
Amylyx Pharmaceuticals has announced that it has appointed Andrew Caldwell to general manager UK and Ireland.
French biotech company StromaCare has announced the appointment of Georges Rawadi as chief executive officer (CEO).
AdhereTech has announced that it has appointed Paul Sekhri to its board of directors, having begun his new role on 7 February 2024.
Cuttsy+Cuttsy has announced the appointment of Jon Hume as commercial director, taking his new role from 1 March 2024.
BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as its new chief executive officer and executive board member, the changes will be effective immediately.
Sosei Group corporation has announced the appointment of Toshihiro Maeda as chief operating officer (COO).
X-Chem has announced that it is making changes to its executive management team, with Karen Lackey, the current chief scientific officer (CSO), becoming chief executive officer (CEO) and Matthew Clark, the current CEO pivoting to the role of president and CSO.
Cellular Origins has announced that it has appointed Peter Crossley as chief operating officer (COO).
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer.
Oxolife has announced that it has appointed globally renowned fertility experts to its scientific advisory board.
IO Biotech has announced the appointment of Helen Collins MD to its board of directors.
NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director.
Pharmaceutical Industry news, analysis and insights